EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold a
conference call on Monday, October 13, to provide an update on the
Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke.
Hosting the call will be Paul E. Freiman, president and chief executive
officer and Warren W. Wasiewski, chief medical officer.
-- Date: Monday, October 13, 2008
-- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT)
-- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942
Telephonic Replay: A playback of the conference call will be available
from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20,
2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International
Pass code: 9164451
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a
biopharmaceutical company focused on developing novel, first-in-class
agents for central nervous system conditions and other serious unmet
medical needs. The Company's most advanced product candidate, Viprinex(TM)
(ancrod), is in Phase 3 clinical testing as a novel investigational drug
for the treatment of acute ischemic stroke. Viprinex has multiple
mechanisms of action and is specifically designed to extend the time period
that patients can be treated after the onset of a stroke. Acute ischemic
stroke is one of the most prevalent, debilitating an
|SOURCE Neurobiological Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved